Celgene (NASDAQ:CELG) Stock Rating Lowered by Vetr

Celgene (NASDAQ:CELG) was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating in a report released on Monday, December 18th. They presently have a $121.72 target price on the biopharmaceutical company’s stock. Vetr‘s target price would suggest a potential upside of 14.83% from the stock’s previous close.

A number of other equities analysts have also weighed in on the stock. Oppenheimer set a $166.00 price objective on shares of Celgene and gave the company a “buy” rating in a research report on Thursday, December 14th. Leerink Swann reissued a “buy” rating and issued a $120.00 target price on shares of Celgene in a report on Wednesday, December 13th. Credit Suisse Group set a $128.00 target price on Celgene and gave the company a “buy” rating in a report on Tuesday, December 12th. Deutsche Bank initiated coverage on Celgene in a report on Tuesday, December 12th. They issued a “hold” rating and a $114.00 target price for the company. Finally, BidaskClub raised Celgene from a “sell” rating to a “hold” rating in a report on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $131.18.

Celgene (NASDAQ CELG) traded up $1.42 during trading hours on Monday, reaching $106.00. 8,748,723 shares of the company were exchanged, compared to its average volume of 6,330,000. Celgene has a 1 year low of $94.55 and a 1 year high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. The stock has a market cap of $83,460.00, a price-to-earnings ratio of 25.00, a price-to-earnings-growth ratio of 0.68 and a beta of 1.77.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene had a net margin of 30.06% and a return on equity of 43.32%. The firm had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period last year, the firm posted $1.58 EPS. Celgene’s quarterly revenue was up 10.2% on a year-over-year basis. equities research analysts anticipate that Celgene will post 6.68 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the company. KCS Wealth Advisory acquired a new position in Celgene in the 4th quarter valued at about $562,000. Addenda Capital Inc. raised its stake in Celgene by 4.8% in the 4th quarter. Addenda Capital Inc. now owns 57,843 shares of the biopharmaceutical company’s stock valued at $6,036,000 after purchasing an additional 2,626 shares during the last quarter. Hikari Power Ltd raised its stake in Celgene by 25.4% in the 4th quarter. Hikari Power Ltd now owns 71,970 shares of the biopharmaceutical company’s stock valued at $7,511,000 after purchasing an additional 14,570 shares during the last quarter. Daiwa SB Investments Ltd. raised its stake in Celgene by 15.9% in the 4th quarter. Daiwa SB Investments Ltd. now owns 10,040 shares of the biopharmaceutical company’s stock valued at $1,048,000 after purchasing an additional 1,380 shares during the last quarter. Finally, Lederer & Associates Investment Counsel CA raised its stake in Celgene by 22.4% in the 4th quarter. Lederer & Associates Investment Counsel CA now owns 17,745 shares of the biopharmaceutical company’s stock valued at $1,852,000 after purchasing an additional 3,246 shares during the last quarter. 79.74% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://ledgergazette.com/2018/01/13/celgene-celg-cut-to-buy-at-vetr.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply